Search
for
Sort by
Research 181–210 of 1000+
- The Association Between Alopecia Areata and Iron Deficiency Anemia: A Large-Scale Population-Based Case–Control Study
- Therapeutic update on alopecia areata: a critical review of standard and emerging targeted therapies
- Considerations for the Treatment Strategy of Relapse After Tofacitinib Therapy in Alopecia Areata
- Significant efficacy of tofacitinib from China in the treatment of alopecia areata: a case report
- Recent Advances in Drug Development for Hair Loss
- Dermatological Indications: Alopecia Areata
- Review on Alopecia Areata in the Middle East and Africa: Landscape and Unmet Needs
- Skin Biology and Ageing
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Dermatologist and Patient Perceptions of Treatment Success in Alopecia Areata and Evaluation of Clinical Outcome Assessments in Japan
- Proteomic Predictors of Baricitinib Response in Severe Alopecia Areata: CCL11 Flags a Refractory Phenotype
- Overlapping features of atopic dermatitis and alopecia areata: from pathogenesis to treatment
- An Updated in the Management of Alopecia Areata
- Alopecia areata: from pathophysiology to therapeutic innovation
- Molecular functional analyses revealed essential roles of HSP90 and lamin A/C in growth, migration, and self-aggregation of dermal papilla cells
- 27604 Response to baricitinib in the treatment of patients with early and late onset alopecia areata in the phase 2 portion of BRAVE-AA1 randomized controlled trial
- 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata
- 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
- Differentiating between Central Centrifugal Cicatricial Alopecia, Traction Alopecia, and Alopecia Areata in Black Patients: Photographic Examples from a Clinical Trial
- Humanized CXCL12 antibody delays onset and modulates immune response in alopecia areata mice: insights from single-cell RNA sequencing
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Keratinocyte-specific ablation of the NF-κB regulatory protein A20 (TNFAIP3) reveals a role in the control of epidermal homeostasis
- Alopecia: Association with Resistance to Thyroid Hormones
- Haarwachstum unter Dupilumab bei Alopecia areata universalis und atopischer Dermatitis
- Gene Expression During Drosophila Wing Morphogenesis and Differentiation
- 52874 Timing of eyebrow and eyelash regrowth among subgroups of scalp responders during treatment of severe alopecia areata with baricitinib
- 52898 Among scalp non-responder patients with eyebrow/eyelash regrowth in the first year, continued treatment with baricitinib resulted in meaningful scalp responses for patients with severe alopecia areata